Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2005-10-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that SNM has a significant effect on brain activity detectable by positron emission tomography (PET).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sacral Neuromodulation in Neurogenic Patients
NCT05688644
Ambulatory Urodynamic Evaluation of Sacral Neuromodulation for Non-Obstructive Urinary Retention
NCT00970242
Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation
NCT02040519
Sacral Neuromodulation & Urodynamics
NCT03614767
Sacral Neuromodulation and the Microbiome
NCT02833402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Baseline neuroimaging
Baseline neuroimaging
Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
B
Neuroimaging during sacral neuromodulation
Neuroimaging during sacral neuromodulation
Neuroimaging during sacral neuromodulation using PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baseline neuroimaging
Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
Neuroimaging during sacral neuromodulation
Neuroimaging during sacral neuromodulation using PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Age \<18 years
* Claustrophobia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Urology, University of Bern, 3010 Bern
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas M Kessler, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Urology, University of Bern, 3010 Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Urology, University of Bern
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1025
Identifier Type: -
Identifier Source: secondary_id
KEK80_05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.